News Business Sports Entertainment Life Obituaries Opinion
Jobs Homes Cars Classifieds Shopping

Search PB Blogs



22 posts categorized "Patent news"

October 01, 2015

A Mayo Clinic linked firm working with DMC planner to develop new Madison biosciences hub

A firm with deep ties to Mayo Clinic is making a move to anchor a downtown Madison, Wis., biosciences hub with help from the development manager of Rochester's Destination Medical Center initiative.

Exact Sciences Corp. licensed technology from Mayo Clinic in 2009 and 2012 for Cologuard, a stool-based DNA test for colorectal cancer. The test is based on research by Mayo Clinic's Dr. David A. Ahlquist and his laboratory.

LogoOriginally based in Boston, city officials at one point hoped Exact would move to Rochester. However, Madison gave the company $1 million to move its headquarters there in 2009.

Since then, the company has flourished, and now it's planning to build a new $200 million, 250,000-square-foot headquarters in downtown Madison with $46.7 million in financial aid from the city.The Madison City Council recently OKed the deal, which requires that Exact will have 400 employees in the building by 2019.

The developer of the project is JDS Development LLC, which is a joint venture between Hammes Co. and Majestic Realty. Hammes is the Wisconsin consultant that is in charge of DMC. It also is working directly with Mayo Clinic on the Discovery Square portion of the DMC project. Hammes also has been hired by the Rochester Convention and Visitors Bureau to do a feasibility study for the proposed hockey arena to house a possible US Hockey League team here.

Hammesco_blue_logoHammes' Exact development will include a 250 room hotel, a food court, health and wellness facility, conference and media centers and lots of room for retail and restaurants.

Exact CEO Kevin Conroy told the Madison City Council that, "We hope that by having a life science company headquarters in downtown Madison, it will spur economic development throughout the region and have a positive impact on downtown."

September 01, 2015

Celyad, Medisun collaborating on new China deal

Two international firms with deep Mayo Clinic and Rochester ties are joining forces for a new $22.4 million collaboration. 

Belgium-based Celyad, formerly called Cardio3, announced Monday it's entering into a new venture and distribution deal with its partner, Medisun International Limited, for its C-Cure cardiac treatment. C-Cure is based on stem-cell technology called cardiopoiesis licensed from Mayo Clinic.

CelyadBoth Celyad and the Hong Kong-based Medisun continue to collaborate with Mayo Clinic and both are in the process of creating facilities in Rochester.

This new 15-year agreement between Celyad and Medisun guarantees Celyad will "conduct all clinical development and undertake any regulatory steps necessary for market approval in China, Hong-Kong, Taiwan and Macau (collectively 'Greater China')," according to a news release about the venture.

Medisun will fund that push with a minimum of 20 million Euros, or $22.4 million. In addition to the funding cash, Celyad will collect royalties and profit sharing. The royalty rates, based on the total revenues from C-Cure, are expected to range from 10 percent to 30 percent. Profit-sharing amounts will be based on total revenues after royalties are taken out. The profit sharing is expected to range from 20 to 25 percent.

"We are pleased to have this new license agreement in place with our local partner Medisun, which give us full control over clinical developments in these territories, fully funded by our local partner. Pending receipt of necessary approvals, we look forward to giving access to this technology to patients in Greater China," stated Celyad CEO Christian Homsy in the release.

6a00d83451cc8269e201b8d0c98293970c-120wiCelyad is paying rent on the entire fifth floor, or 14,963 square feet, in the city of Rochester's Minnesota Biobusiness Center. The city signed a lease with Celyad earlier this year for it to develop a prototype manufacturing facility in the downtown building. Construction has been underway for months, but is not yet completed. The five-year lease calls for Celyad to pay a rent of $18 per square foot, or $22,444.50 per month. The city agreed in the lease to pay for $600,000 in equipment and improvements to the space.

Local officials hope to convince Celyad to build a 100,000-square-foot manufacturing facility with 350 employees in Rochester, according to officials at Rochester Area Economic Development Inc.  Celyad also has plans to build a U.S. headquarters in Boston.

The company recently reported a $17.04 million loss for the first half of 2015. It lost $18.1 million for the whole year in 2014, up from $15.9 million in losses in 2013. Dr. Homsy told Reuters last week the company has enough cash to make it through the end of 2017.

The company did an initial public stock offering in 2014, which yielded about $500,000 worth of shares for Mayo Clinic.

Medisun also is collaborating with Mayo Clinic on a project to bring more patients from China to Rochester for treatment. While Medisun began building a $1 million office in the H3 Plaza building in downtown Rochester earlier this year, it recently put an end to that project.

Mayo Clinic, however, has confirmed it still is working with Medisun. Mayo Clinic spokeswoman Duska Anastasijevic said she didn't believe "the scope and nature of the relationship has been impacted or altered, just the planned location of their offices has changed." 

She added that Mayo staff working with Medisun said the company will be using one of its Rochester homes as "a guest house" and headquarters for the project. Medisun CEO Danny Wong personally owns two houses in Rochester. He bought a house at 2515 Crest Lane SW for $1.4 million as well as one at 615 10th Ave. SW for $1.31 million. It is not known which property will serve as the guest house.

March 26, 2015

Cardio3 reports losing $18 million in 2014

Cardio3 released a financial report today with a lot of interesting tidbits like it's building in the Minnesota BioBusiness Center due to an agreement with Mayo Clinic.

Also it's developing a U.S. headquarters… in Boston.

Here's most of my article on this:

The Belgium-based biotech firm building a manufacturing facility in downtown Rochester reported today that it lost $18.1 million in 2014, up from the $15.9 milCardiobioscience_jpeglion it lost in 2013.

Cardio3 BioSciences, which works closely with Mayo Clinic and is taking over the fifth floor of the Minnesota BioBusiness Center, reported its financials for 2014, plus some highlights of its activities in 2015.

Cardio3 is publicly listed on the European stock markets of NYSE Euronext Brussels and NYSE Euronext Paris, although it is not traded publicly in the United States.

Mayo Clinic owned 2.69 percent of Cardio3, as of March 3. Mayo Clinic first acquired equity in Cardio3 in 2007, when it licensed stem cell research by Mayo Clinic's Dr. Andre Terzic and Dr. Atta Behfar. Its cardiopoiesis technology repairs patients' hearts by re-programming their own stem cell to regenerate cardiac tissue.

6a00d83451cc8269e201a511d8e824970c-250wiThe Hong Kong-based Medisun, which is opening an office in Rochester, owned 7.2 percent of Cardio3 on March 3.

In the years since 2007, Mayo Clinic has developed a close working relationship with the Belgian company. Mayo Clinic is participating the U.S. clinical trial of Cardio3.

"We made significant strategic, operational and financial advancements in 2014 as we seek to build C3BS into a global specialty therapeutics company," stated Cardio3 CEO Dr. Christian Homsy in the announcement.

The annual report highlighted "a non-exclusive preferred access agreement" signed with Mayo Clinic in October that cleared the way for Cardio3 to build a facility in the City of Rochester's BioBusiness Center building.

"With this agreement, Cardio3 BioSciences agreed to give preferred consideration for Rochester, Minnesota to the U.S. to build a manufacturing facility for the production of C-Cure, at a facility located adjacent to the campus of the Mayo Clinic, and the Mayo Clinic agreed to periodically review with Cardio3 BioSciences its portfolio of regenerative medicine technologies, including in the areas of cardiology and oncology, with a view towards future potential licensing," according to the Cardio3 report.

Cardio3's prototype manufacturing facility will occupy the 14,963-square-feet of space on the fifth floor of the downtown building. Mayo, which leases the fourth through eighth floors, moved its employees out of the fifth floor earlier this year. Cardio3's five-year lease calls for it to pay a rent of $18 per square foot, or $22,444.50, per month. The city agreed to pay for $600,000 in equipment and improvements to the space.

The Minnesota Department of Employment and Economic Development also agreed to give Cardio3 a Minnesota Job Creation Fund award of $357,000, if the company invests $1.5 million in Rochester within a year and hires 33 employees within two years.

The ultimate goal of this project is for the city and RAEDI to eventually convince Cardio3 to build a 100,000-square-foot manufacturing facility with 350 employees in Rochester, according to officials at RAEDI.

However, Rochester is not the only city wooing the Belgium company. While the Rochester facility is Cardio3's first official U.S. location, the company's report show that it also has plans to build a U.S. headquarters in Boston, Mass.

The company also reported that it's re-stating its 2013 financial reports "to reflect errors" found by PriceWaterhouseCoopers.

"After due consideration with its auditors, we decided that the shareholders convertible loans should have been accounted for as a financial debt instead of equity (previously called 'quasi equity') as originally posted in our 2013 financial statements, because the loans were convertible into a variable number of shares," according to today's statement from the company.

January 15, 2015

Roch. start-up licenses virus to pharmaceutical giant

An international pharmaceutical giant has signed a deal to license a cancer-killing virus from Rochester drug company.

MedImmune, which is owned by London-based AstraZeneca, is licensing a genetically engineered strain of the vesicular stomatitis virus from Omnis Pharmaceuticals. Omnis is a Rochester start-up founded by Dr. Stephen J. Russell, Dr. Kah-Whye Peng, Shruthi Naik and Mark Federspiel, who all work at Mayo Clinic in Rochester. A fifth founder, Glen Barber, is based at the University of Miami.

The companies now will collaborate to combine the Omnis virus with a check point inhibitor created by MedImmune. The goal is to eventually create a treatment for types of cancer affecting the liver, but potentially could be developed to treat a broad array of cancers.

"For us, it's a very big and very important step forward," Omnis CEO Russell said. "Essentially, we have AstraZeneca/MedIummune saying, 'We love this lead product of yours. We want to pick it up, cover the development costs and run with you to bring it to market.' That's a huge accelerator for this development program."

He explained that oncolytic viruses, similar to the one MedImmune is licensing from Omnis, have been found to be effective in destroying cancer cells. Many companies, in the U.S. and internationally, are working on their own treatment based on viruses.

"That's why they're excited about this virus. They can inject it directly into a tumor and kill tumor cells. That wakes up immune system, which adds to the attack," Russell said. "Then if you get the check point inhibitor antibody, the hope is that will lead to major tumor destruction."

This collaboration could mean a lot to Rochester. The US cancer vaccine market was estimated in 2012 to be worth about $14 billion. With about 1.5 million Americans being diagnosed with cancer every year, that market could possibly grow to reach $20 billion by 2020.

While the companies declined to release any financial details of the deal, it's clear the upfront payment portion of the agreement has given Omnis a boost to pursue its own goals, parallel to MedImmune project.

"Our obsession, if you like, is to develop viruses that could be given as systemic intravenous anti-cancer therapy," Russell said.

This virtual start-up, which was founded in late 2013, is "based" on the first floor the Minnesota BioBusiness Center in downtown Rochester in the facilities of Imanis Life Sciences.

Imanis is a related company that was founded by Russell, Peng and Dennis E. Young. It launched in the Mayo Clinic Business Accelerator on the second floor of the building and soon leased 1,736-square-feet of space for its offices and a "wet lab." Imanis makes genetic tracking agents for use in medical research. It also does medical imaging and conduct experiments for clients.

Russell said while Omnis has a lot of potential to break new ground scientifically, Imanis is the more likely candidate to grow into a economic driver and job creator in Rochester.

"That company (Imanis) will probably grow to occupy a fairly large footprint. This company (Omnis) is less likely to arrive at that point," he said.

In 2015, Peng said, "We hope to build it faster to up to 30 to 50 people as we do more manufacturing. We hope to be able to keep it in downtown Rochester. This is our home."

The group also has a third virtual start-up company called Magnis Therapeutics, which is working on a cancer treatment based on the measles virus.

Having three companies with names that end in "-nis" seemed like a good idea at first, said Russell with chuckle. But now, he admits it might be a bit confusing.

November 14, 2014

Ex-Mayo doc "feared retribution against himself and his family"

It has been an interesting week in the Mayo Clinic vs Dr. Franklin Cockerill legal tussle. So Cockerill's lawyers filed a motion Wednesday to modify the temporary restraining order that blocks Cockerill from working for Quest Diagnostics PLUS a detailed affidavit from Cockerill explaining his side of the case.

So the PB court reporter Kay Fate printed out the documents for me on Thursday and I wrote an article based on the filings last night. The twist here is that Cockerill's legal team withdrew the filings Thursday, after we printed them out.

The upshot is that my article is still running today in the PB. Here's some of it. The full piece is in today's paper:

A former Mayo Clinic doctor and executive said he did not tell Dr. John Noseworthy about his plans to work for a Mayo competitor because he "feared retribution against himself and his family."

CockerillDr. Franklin R. Cockerill III, the former CEO of Mayo Medical Labs, took early retirement at the end of September. However, instead of retiring, he stepped into a new job on Oct. 1 with Quest Diagnostics Inc.

The clinic filed a lawsuit against Cockerill over his decision to not tell Mayo Clinic he had been hired by a competitor; he told co-workers he intended to run his elderly mother's farming business.

The suit claims he misled everyone so he could acquire sensitive competitive information for his new employer. As part of that suit, a temporary restraining order was issued on Oct. 14 that prevented him from working at Quest because he could cause "irreparable harm" to Mayo Clinic.

Members_009-questCockerill filed a motion Wednesday to modify that order to allow him begin his role as Quest's chief lab officer because the person he is to replace will retire at the end of December. However, his lawyers withdrew the filing on Thursday and also withdrew an affidavit that detailed his version of the events surrounding his departure from Mayo after a more than 30-year career there.

However, the withdrawal came after the Post-Bulletin obtained a copy of the affidavit.

"It is now plain that the draconian restrictions that Plaintiffs obtained from this Court and that Dr. Cockerill had no opportunity to oppose are not consistent with Minnesota law and are entirely inappropriate," according to the original filing made by his lawyers from the Minneapolis firm of Lindquist & Vennum.

Cockerill contends Mayo Clinic had approached him with an attractive early retirement offer as his final two-year term as a department head was coming to an end. When asked for a response, Mayo Clinic denied that.

"Claims of an early retirement offer are completely false, and we were prepared to file documentation to prove it," said Mayo spokesman Bryan Anderson this morning.

In his affidavit, Cockerill says he announced his retirement in July, with plans to help his mother, and then he was asked by a Quest recruiter to interview for a position there. He eventually accepted a job with the condition that he work from Rochester, instead of the company's New Jersey headquarters.

Cockerill stressed in his filing he did not make the change to make more money. Mayo Medical Labs is the third largest laboratory company in U.S. and generates "a significant proportion of Mayo's profits." He had made about $580,000 a year at Mayo Clinic. At Quest, he will earn an annual salary of $400,000.

"I left my employment at Mayo reluctantly and only due to the convergence of several factors that arose as I enter the last stages of my professional career," he wrote in the filing. "Finally, in addition to limitation on the role I could still play at Mayo, my interest in the Quest position, and the attractive Mayo early-retirement offer, my decision to change employment was also influenced by my belief that the environment at Mayo had negatively changed over the past five years. Staff satisfaction has declined, burnout has significantly increased, and many people have grown afraid to speak up and voice their opinions."

October 15, 2014

Ex-Mayo exec accused of stealing trade secrets

A former top Mayo Clinic executive is being sued for allegedly hiding his hiring by a competitor of Mayo Medical Laboratories for months while he continued to work for Mayo and for stealing trade secrets.

Franklin-cockerillMayo Clinic filed a lawsuit alleging misappropriation of trade secrets and breach of contract against Dr. Franklin R. Cockerill III, who was president and chief executive officer of the for-profit Mayo Medical Labs for eight years. The case was filed Tuesday in Olmsted County District Court. Mayo Clinic released the lawsuit to the media this morning.
A Mayo Clinic statement released by Bryan Anderson this morning said, “We do not take this action lightly. Dr. Cockerill was a valued Mayo Clinic clinician, leader and colleague.  We will vigorously defend and protect our intellectual property to ensure we can continue to meet our charitable mission,"

A call to Dr. Cockerill's southwest Rochester residence went unanswered this morning. Asked to comment, Quest Director of Media Relations Wendy Bost said the company received the complaint this morning and is reviewing it. "We do not comment on pending litigation," Bost said.

According to the complaint:

On July 17, an emotional Cockerill told his department that he was "retiring" to help his 85-year-old mother run her fertilizer business in Nebraska. Co-workers lauded his almost 30-year career with Mayo Clinic and gave him an appreciative send-off that built up to his final day of work on Sept. 30.

All of that changed on Oct. 1. Instead of retiring to Nebraska, Cockerill went to New Jersey to work for a major MML competitor, Quest Diagnostics Inc. He stepped into the position of vice president and chief laboratory officer for the multibillion public company.

Using emails as evidence, Mayo Clinic contends Cockerill had been talking to Quest about a job since February. He had a phone interview with Quest in March followed by a face-to-face interview in May, when Cockerill said he needed the time off to help his mother with a business problem. The lawsuit alleges he accepted the Quest position in June. Instead of informing Mayo Clinic, he continued to work at Mayo and attend confidential meetings, where issues were discussed that could cause irreparable damage to MML and Mayo Clinic in the hands of Quest.

Cockerill exchanged emails discussing business strategies with Quest CEO Stephen Rusckowski in August, according to Mayo's suit.

Mayo Clinic alleges Cockerill left with at least seven clinic-owned USB memory drives and that he used four of them to "download information from Dr. Cockerill's computer in the days before … (he) started working for Quest."

Mayo Medical Labs and Quest vie for millions in medical test contracts. Mayo Medical Labs performs about 20 million tests for more than 4,000 hospitals annually. Quest says it does 1.5 billion tests a year. Many of the clinical tests conducted by both MML and Quest are proprietary and generate millions in revenue.

The lawsuit also claims Cockerill attempted to recruit "at least one long-term key Mayo employee to consider retiring early to 'consult' with the lab industry," though he did not specifically mention Quest to the female executive.

July 01, 2014

Mayo Clinic-linked Cardio3 making push into China

Cardio3 BioSciences, a Belgium company working closely with Mayo Clinic, recently launched a joint venture in China, the third largest pharmaceutical market in the world.

Cardiobioscience_jpegWorking with Hong Kong-based Medisun International Limited, it created Cardio3 BioSciences Asia Holdings Ltd. to make a serious push into China. As part of the deal, Medisun purchased $34 million in stock. It now owns 8 percent of the company's outstanding shares.

Cardio3 is publicly listed on the European stock markets NYSE Euronext Brussels and NYSE Euronext Paris, though it is not traded publicly in the U.S. Get_photo

The company says that $34 million will finance the U.S. clinical trials for C-Cure, Cardio3's regenerative heart treatment. Cardio3 CEO Dr. Christian Homsy flew to Rochester in January for a press conference at Mayo Clinic to announce that U.S. trial. Mayo Clinic in Rochester is one of the trial sites. Homsy gave a tentative time line of commercialization in Europe possibly by 2017 and by 2018 in the U.S.

Medisun has also committed to buy an additional $34 million shares of Cardio3 stock from existing shareholders in the next eight month at a price per share equivalent to the 10 days average preceding the offer.

This new deal means Medisun's ownership of Cardio3 has quickly leapfrogged Mayo Clinic's investment. As of June 16, Mayo Clinic owned 5.05 percent of the available shares of Cardio3. Medisun had just 4.21 percent at that point. As of June 25, Mayo Clinic controlled 3.1 percent of the shares.

Mayo Clinic researchers Dr. Andre Terzic and Dr. Atta Behfar originally developed the proprietary process of regenerating heart tissue with stem cells drawn from a patient's own bone marrow. Since 2007, Cardio3 has licensed patents and related research from Mayo Clinic. Terzic and Behfar each have a financial interest in the company.

Homsy has previously stated that he hopes to eventually base a few employees in Rochester for office and laboratory work. Cardio3 previously attempted to open a U.S. headquarters here, but that fizzled when the one person based here left.

Many consider what Cardio3 is attempting as the "holy grail" of cardiac treatments. Terzic previously described repairing faulty hearts as a "major unmet need worldwide." He estimated about one-third of all deaths stem from heart disease.

To date, the promising company has raised $121 million in equity and capital.

A recent study also estimated that the global market for such treatments could grow to $18.2 billion by 2019. The U.S. market was valued at $6.1 billion in 2012, with potential to increase to $8.49 billion by 2019.

“With this presence in Greater China, we are very proud to become the first global player in the field of cardiac regenerative medicines, aiming to commercialize our leading edge cell therapy to patients all across the globe,” stated Cardio Chairman Michel Lussier in the announcement of the venture.

Medisun Chairman Danny Wong says that his company is organizing medical conventions in August "to promote cell based medicines as well as Cardio3’s technology" in both Beijing and Shanghai.

"We are passionate about this project and I am certain that our involvement with Cardio3 as a leader in this field, combined with our local knowledge of the regulatory, healthcare and market access capabilities and expertise, will bring success to all the parties involved,” said Wong.

All the costs of Cardio3's moves in China will be funded by Medisun, with a minimum of $27 million committed during a three year period. Cardio 3 has 40 percent ownership in the joint venture, which will drop to 30 percent when clinical trials are up and running.

Success of the Phase III clinical trials that allow Cardio3 to market C-Cure in Asia would trigger  royalties ranging between 20 and 30 percent of net sales depending on total revenue of the joint venture.

April 08, 2014

Mayo Clinic's Nobel Prize work at heart of $5.6B drug deal

So Questcor Pharmaceuticals announced Monday that Ireland-based Mallinckrodt Pharmaceuticals is buying it for a whopping $5.6 BILLION.

A little research into Questcor shows that it has followed an interesting path starting with its $100,000 purchase of rights to H.P. Acthar Gel from Aventis in 2001. The FDA then approved labeling Acthar as "an orphan drug," which opened up the company's options for pricing Acthar.

The New York Times says the price per vial climbed from $40 to an incredible $28,000 within 10 years.

CortisoneA95D4FE2FBE5At the core of Questcor's story is one of Mayo Clinic's most famous research successes.

In 1948, Dr. Philip S. Hench and Dr. Edward C. Kendall were studying the effects of a hormone on inflammination related to rheumatoid arthritis. They had success with cortisone, but it was difficult to synthesize.

Hench then injected adrenocorticotropic hormone, or ACTH to cause the patient's body to produce their own cortisone and other steroid hormones. The ACTH came from pigs from Armour meatpacking.

In 1950, Hench and Kendall won the Nobel Pirze in medicine for their research. Unfortunately, they didn't patent it. The FDA approved H.P. Acthar Gel to treat a variety of diseases and conditions. It was then owned by the meatpacker Armour.

In recent years, Questcor has been criticized for its dramatic price hikes and for vauge allusions to "a secret sauce" in their drug that improves its effectiveness.

Some question if it is effective at all.

Mayo Clinic's Dr. Eric Matteson, the chairman of rheumatology, has been quoted about the use of Achtar in rheumatolgy.

• “Limited to no attractiveness in rheumatology”

• “Enthusiasm is low”

• "Very little if any role for an ACTH product in rheumotatic diseases, I don't see it."

December 05, 2013

Breast cancer scanner maker, once linked to Mayo Clinic, sold to Mexican company

Qg3q4q112233Here's a potentially interesting nugget of news about San Diego-based Naviscan Inc., which was at one pointed linked with Mayo Clinic through intellectual property licenses as well as direct investment by Mayo Medical Ventures.

"… Certain Naviscan Inc. assets including intellectual property and the Naviscan Trademark" have been aquired by a Mexican medical scanner company called Compañía Mexicana de Radiología or CMR.

Not sure what that means exactly, but my guess is that CMR is now behind the steering wheel at Naviscan.

Now I don't know if Mayo Clinic still has any links with Naviscan, but it certainly did at one time. I've got calls into Mayo and Naviscan to check on that.

I wrote the Mayo Clinic-Naviscan relationship back in 2005 through 2007 or so. Sheesh, I've been doing this for a long time.

From back in November 2005:

Naviscan “entered into an agreement with Mayo Foundation for Medical Education and Research (Mayo Clinic) to clinically validate and commercialize a dynamic patented molecular imaging agent for use with Positron Emission Tomography (PET) and other imaging modalities. … Mayo Clinic has licensed the vitamin B-12 molecular imaging agent technology invented by Dr. Douglas A.Collins to Naviscan PET Systems, Inc and will receive royalties from this license. Researchers at the Mayo Clinic have published studies that cancers have high uptake of radioactive B-12, especially in breast tumors."

"The combination of the Mayo Clinic’s patented Vitamin B-12 molecular imaging agent and Naviscan’s high-resolution PET scanner holds great promise for the future in terms of early detection of breast cancers,” said Paul Grayson, newly-appointed CEO of Naviscan PET Systems, Inc. and a Managing Director of Sanderling Ventures. “We sought out Naviscan’s technology to strategically invest in this important imaging technology platform.” Naviscan is planning clinical trial work with Mayo Clinic and other luminary sites in the U.S. to prove the value of the PEM Flex in breast cancer patients, as well as for evaluating PEM’s role with high-risk patients.”


From the same date in 2005:

“Naviscan PET Systems has raised a $6.5 million in Series B funding for its high resolution positron emission tomography (PET) products. The firm said that it raised the round from Sanderling Ventures, with participation from Mayo Medical Ventures."

FYI, Sanderling Ventures now leases a space in the Mayo Clinic Business Accelerator.

March 11, 2013

Mayo Clinic extends deal with drug research lab

Here's some from a release I spotted this morning about Mayo Clinic signing an updated agreement with Sanford-Burnham, a research lab with locations in California and Florida.

By the way, the Sanford in Sanford-Burnham is T. Denny Sanford, who is also a big financial backer of Mayo Clinic.

Sanford-Burnham and Mayo Clinic signed a new collaborative agreement to build a pipeline of therapeutic drugs aimed at a variety of diseases with serious unmet medical needs.


Sanford-burnhamThe agreement combines Mayo Clinic’s clinically relevant targets with Sanford-Burnham’s discovery platform in a translational initiative aimed at advancing a portfolio of projects through the initial stages of drug discovery. The new agreement builds on a yearlong pilot phase and expands the number and scope of drug discovery projects derived from Mayo Clinic researchers that are being conducted at Sanford-Burnham.
“We’re looking forward to further engaging with our Mayo Clinic collaborators as we develop innovative screens to identify chemical compounds that modulate the activity of clinically relevant targets,” said Michael Jackson, vice president of drug discovery and development at Sanford-Burnham. “If successful, these compounds will form the basis of completely novel—‘first in class’—therapies for devastating diseases such as cancer, Alzheimer’s, and others.”
“The Mayo Clinic–Sanford-Burnham collaboration provides an avenue for Mayo scientists to rapidly translate basic science discoveries into screening platforms that will enable new drug discovery, and a new paradigm in drug development,” said Andrew Badley, associate dean of research resources at Mayo Clinic.